Replies to post #223452 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

You've read the slide a million times. She states that for immunotherapy trials, endpoints may be different than for regular trials. Then she gives the example:

"Hazard ratio of long term survival versus one-year OS difference."